Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NTHI vaccine GSK2838500A (formulation 1)
NTHI vaccine GSK2838500A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects in this group will receive formulation 1 of NTHi vaccine. |
| Group B | EXPERIMENTAL | Subjects in this group will receive formulation 2 of NTHi vaccine. |
| Group C | EXPERIMENTAL | Subjects in this group will receive formulation 3 of NTHi vaccine. |
| Group D | EXPERIMENTAL | Subjects in this group will receive formulation 4 of NTHi vaccine. |
| Group E | EXPERIMENTAL | Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo. |
| Group F | EXPERIMENTAL | Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo. |
| Group G | EXPERIMENTAL | Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo. |
| Group H | EXPERIMENTAL | Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo. |
| Group Placebo 1 | PLACEBO_COMPARATOR | Subjects in this group will receive placebo. |
| Group Placebo 2 | PLACEBO_COMPARATOR | Subjects in this group will receive placebo. |
| Name | Type | Description |
|---|---|---|
| NTHI vaccine GSK2838500A (formulation 1) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838501A (formulation 2) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838502A (formulation 3) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838503A (formulation 4) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838504A (formulation 5) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838505A (formulation 6) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838508A (formulation 7) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| NTHI vaccine GSK2838509A (formulation 8) | BIOLOGICAL | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
| Placebo comparator | DRUG | Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule. |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * A male or female between, and including, 50 and 70 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * Subjects...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Roivant Sciences Ltd. | ROIV | 2 | PHASE2 | Mosliciguat |
NTHI vaccine GSK2838500A is an investigational vaccine developed by GSK plc for respiratory disorders. It is designed to target non-typeable Haemophilus influenzae (NTHi), a bacterium associated with respiratory infections. The vaccine is in Phase 1 clinical development and has been studied in current and former smokers.
NTHI vaccine GSK2838500A is being developed for the prevention of respiratory disorders associated with non-typeable Haemophilus influenzae (NTHi). It is intended for use in adults, particularly current and former smokers aged 50 years and older, who are at risk of respiratory infections.
NTHI vaccine GSK2838500A is being developed by GSK plc, a global pharmaceutical company. GSK plc is listed on the New York Stock Exchange under the ticker symbol GSK. The company is responsible for the research and clinical development of this investigational vaccine.
NTHI vaccine GSK2838500A is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently approved for any indication. As an investigational vaccine, it remains under clinical evaluation for safety, reactogenicity, and immunogenicity.
NTHI vaccine GSK2838500A has been evaluated in a single Phase 1 clinical trial, NCT01678677. This completed trial enrolled 272 participants in Belgium to assess the safety, reactogenicity, and immunogenicity of the vaccine in current and former smokers aged 50 years and older.
Yes, NTHI vaccine GSK2838500A is also known as NTHI vaccine GSK2838500A (formulation 1). The parenthetical designation distinguishes this specific formulation from other potential formulations. Both names refer to the same investigational vaccine developed by GSK plc for respiratory disorders.